These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 21040895)

  • 1. Stem cells and osteoporosis therapy.
    Teitelbaum SL
    Cell Stem Cell; 2010 Nov; 7(5):553-4. PubMed ID: 21040895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
    Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
    Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous delivery of BMP-2 factor and anti-osteoporotic drugs using hyaluronan-assembled nanocomposite for synergistic regulation on the behaviors of osteoblasts and osteoclasts in vitro.
    Zhang Y; Hu Y; Luo Z; Shen X; Mu C; Cai K
    J Biomater Sci Polym Ed; 2015; 26(5):290-310. PubMed ID: 25585099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling.
    Wu X; Pang L; Lei W; Lu W; Li J; Li Z; Frassica FJ; Chen X; Wan M; Cao X
    Cell Stem Cell; 2010 Nov; 7(5):571-80. PubMed ID: 21040899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the systemic administration of alendronate on bone formation in a porous hydroxyapatite/collagen composite and resorption by osteoclasts in a bone defect model in rabbits.
    Sugata Y; Sotome S; Yuasa M; Hirano M; Shinomiya K; Okawa A
    J Bone Joint Surg Br; 2011 Apr; 93(4):510-6. PubMed ID: 21464492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Giant osteoclast formation and long-term oral bisphosphonate therapy.
    Roos JC; Cox TM
    N Engl J Med; 2009 Apr; 360(16):1676-7; author reply 1677-8. PubMed ID: 19373965
    [No Abstract]   [Full Text] [Related]  

  • 7. The deceiving appearances of osteoclasts.
    Glowacki J
    N Engl J Med; 2009 Jan; 360(1):80-2. PubMed ID: 19118309
    [No Abstract]   [Full Text] [Related]  

  • 8. Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation.
    Jin J; Wang L; Wang XK; Lai PL; Huang MJ; Jin DD; Zhong ZM; Chen JT; Bai XC
    J Surg Res; 2013 Mar; 180(1):e21-9. PubMed ID: 22487394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate enhances osseous healing in a rat calvarial defect model.
    Toker H; Ozdemir H; Ozer H; Eren K
    Arch Oral Biol; 2012 Nov; 57(11):1545-50. PubMed ID: 22795567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of alendronate on bone formation and osteoclastic resorption after implantation of beta-tricalcium phosphate.
    Tanaka T; Saito M; Chazono M; Kumagae Y; Kikuchi T; Kitasato S; Marumo K
    J Biomed Mater Res A; 2010 May; 93(2):469-74. PubMed ID: 19582838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biology of the basic multicellular unit and the pathophysiology of osteoporosis.
    Jilka RL
    Med Pediatr Oncol; 2003 Sep; 41(3):182-5. PubMed ID: 12868116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture.
    Bagi CM; Volberg M; Moalli M; Shen V; Olson E; Hanson N; Berryman E; Andresen CJ
    Anat Rec (Hoboken); 2007 Aug; 290(8):1005-16. PubMed ID: 17610276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis.
    Armamento-Villareal R; Napoli N; Panwar V; Novack D
    N Engl J Med; 2006 Nov; 355(19):2048-50. PubMed ID: 17093260
    [No Abstract]   [Full Text] [Related]  

  • 15. Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.
    Giner M; Rios MJ; Montoya MJ; Vázquez MA; Miranda C; Pérez-Cano R
    Eur J Pharmacol; 2011 Jan; 650(2-3):682-7. PubMed ID: 21050847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoclast activation: potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism.
    Owens JM; Fuller K; Chambers TJ
    J Cell Physiol; 1997 Jul; 172(1):79-86. PubMed ID: 9207928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis.
    Elabd C; Basillais A; Beaupied H; Breuil V; Wagner N; Scheideler M; Zaragosi LE; Massiéra F; Lemichez E; Trajanoski Z; Carle G; Euller-Ziegler L; Ailhaud G; Benhamou CL; Dani C; Amri EZ
    Stem Cells; 2008 Sep; 26(9):2399-407. PubMed ID: 18583541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct VEGF functions during bone development and homeostasis.
    Liu Y; Olsen BR
    Arch Immunol Ther Exp (Warsz); 2014 Oct; 62(5):363-8. PubMed ID: 24699630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of severe osteoporosis with alendronate in a patient with lysinuric protein intolerance.
    Gömez L; García-Cazorla A; Gutiérrez A; Artuch R; Varea V; Martín J; Pinillos S; Vilaseca MA
    J Inherit Metab Dis; 2006 Oct; 29(5):687. PubMed ID: 16868861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a novel osteoporotic drug delivery system in vitro: alendronate-loaded calcium phosphate cement.
    Jindong Z; Hai T; Junchao G; Bo W; Li B; Qiang WB
    Orthopedics; 2010 Aug; 33(8):. PubMed ID: 20704104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.